🧐 ProPicks AI October update is out now! See which stocks made the listPick Stocks with AI

UPDATE 3-Australia says not worried about AstraZeneca's suspension of COVID vaccine trials

Published 09/09/2020, 10:13 am
Updated 09/09/2020, 07:12 pm
© Reuters.
CSL
-
AZN
-

* Vaccine trial on hold due to unexplained illness

* Victoria new daily case numbers highest in three days

* Cases in regional Victoria ease further (Adds comments from Victoria premier, new case numbers)

By Renju Jose

SYDNEY, Sept 9 (Reuters) - AstraZeneca Plc's AZN.L suspension of its COVID-19 vaccine trials after a participant's unexplained illness did not mean the vaccine had been scrapped and showed safety standards were being adhered to, Australia's deputy chief medical officer said on Wednesday.

The British drugmaker said it voluntarily paused trials to allow an independent committee to review safety data, and it was working to expedite the review.

The New York Times cited a person familiar with matter as saying the illness was transverse myelitis, an inflammatory syndrome that affects the spinal cord and is often sparked by viral infections. AstraZeneca did not disclose the illness and declined to comment on the report.

"With the information that I have got at the moment, I am not worried about it," Nick Coatsworth, the country's deputy chief medical officer told Sky News, adding the pause does not mean the vaccine "is off the table".

"In some respects, this is a very positive thing because it shows that despite the accelerated vaccine development, safety is the priority of the clinical trialists and investigators," he said.

While Australia has ordered millions of doses if the vaccine proves successful, Coatsworth said the country had invested in several inoculation candidates "knowing not all of them will get through". Australian state at the centre of the country's coronavirus outbreak, Victoria, reported 76 new cases on Wednesday, its biggest rise in daily cases in three days although average daily case numbers in regional areas were declining.

Regional Victoria was "on the cusp" of meeting its target average rate of new infections to justify easing restrictions on Sept. 14, state Premier Daniel Andrews told a news conference. A higher-level lockdown of Melbourne will end on Sept. 28 at the earliest.

Victoria, home to one-quarter of Australia's 25 million population, now accounts for about 75% of the country's almost 26,500 COVID-19 cases and 90% of its 781 deaths.

New South Wales, the country's most populous state, logged nine new daily cases, while the northern state of Queensland reported eight.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.